Compare MXCT & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | ORMP |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 160.6M |
| IPO Year | 2021 | 2010 |
| Metric | MXCT | ORMP |
|---|---|---|
| Price | $1.38 | $3.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.11 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 117.4K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 6.78% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 3.17 |
| Revenue | ★ $33,026,000.00 | $2,000,000.00 |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | ★ N/A | $1.16 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $0.64 | $2.52 |
| 52 Week High | $1.80 | $5.47 |
| Indicator | MXCT | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 32.96 |
| Support Level | $1.02 | $3.55 |
| Resistance Level | $1.54 | $3.72 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 70.41 | 9.86 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.